COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,323

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

February 14, 2022

Study Completion Date

February 14, 2022

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

Metformin

Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.

DRUG

Placebo

placebo; appearance and size are exact matching to the three study drugs.

DRUG

Fluvoxamine

An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14

DRUG

Ivermectin

An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days

Trial Locations (7)

46140

American Health Network of Indiana, Greenfield

55415

Hennepin County Medical Center, Minneapolis

55455

University of Minnesota, Minneapolis

60611

Northwestern University Feinberg School of Medicine, Chicago

80045

University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center, Aurora

80401

New West Physicians, Golden

91342

Olive View UCLA Medical Center, Sylmar

All Listed Sponsors
collaborator

UnitedHealth Group

INDUSTRY

collaborator

Northwestern University

OTHER

collaborator

Hennepin County Medical Center, Minneapolis

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

Olive View-UCLA Education & Research Institute

OTHER

lead

University of Minnesota

OTHER

NCT04510194 - COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) | Biotech Hunter | Biotech Hunter